Ceftazidime-Avibactam as Salvage Treatment for Infections Due to Carbapenem-Resistant Klebsiella pneumoniae in Liver Transplantation Recipients

References

• Lübbert C, Becker-Rux D, Rodloff AC, et al. Colonization of liver transplant recipients with KPC-producing Klebsiella pneumoniae is associated with high infection rates and excess mortality: a case-control analysis. Infection. 2014;42(2):309–316. doi:10.1007/s15010-013-0547-324217959
   PubMed Web of Science ®Google Scholar
• Giannella M, Bartoletti M, Morelli MC, et al. Risk factors for infection with carbapenem-resistant Klebsiella pneumoniae after liver transplantation: the importance of pre- and posttransplant colonization. Am J Transplant. 2015;15(6):1708–1715. doi:10.1111/ajt.1313625754742
   PubMed Web of Science ®Google Scholar
• Carrion AF. Risk factors and outcomes of carbapenem-resistant Klebsiella pneumoniae infections in liver transplant recipients. Liver Transplant. 2016;22(5):698–699. doi:10.1002/lt.24413
   Web of Science ®Google Scholar
• Huprikar S. Update in infectious diseases in liver transplant recipients. Clin Liver Dis. 2007;11(2):337–354. doi:10.1016/j.cld.2007.04.00617606211
   PubMedGoogle Scholar
• Varghese J, Jayanthi V, Rela M. Mortality associated with carbapenem-resistant Klebsiella pneumoniae infections in liver transplant recipients. Liver Transplant. 2012;18(9):1124;author reply 1125. doi:10.1002/lt.23464
   Web of Science ®Google Scholar
• Linares L, Cervera C, Hoyo I, et al. Klebsiella pneumoniae infection in solid organ transplant recipients: epidemiology and antibiotic resistance. Transplant Proc. 2010;42(8):2941–2943. doi:10.1016/j.transproceed.2010.07.08020970577
   PubMed Web of Science ®Google Scholar
• Bergamasco MD, Barroso Barbosa M, de Oliveira Garcia D, et al. Infection with Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae in solid organ transplantation. Transplant Infect Dis. 2012;14(2):198–205. doi:10.1111/j.1399-3062.2011.00688.x
   PubMed Web of Science ®Google Scholar
• Mouloudi E, Massa E, Piperidou M, et al. Tigecycline for treatment of carbapenem-resistant Klebsiella pneumoniae infections after liver transplantation in the intensive care unit: a 3-year study. Transplant Proc. 2014;46(9):3219–3221. doi:10.1016/j.transproceed.2014.09.16025420864
   PubMed Web of Science ®Google Scholar
• Hand J, Patel G. Multidrug-resistant organisms in liver transplant: mitigating risk and managing infections. Liver Transplant. 2016;22(8):1143–1153. doi:10.1002/lt.24486
   Web of Science ®Google Scholar
• Barchiesi F, Montalti R, Castelli P, et al. Carbapenem-resistant Klebsiella pneumoniae influences the outcome of early infections in liver transplant recipients. BMC Infect Dis. 2016;16(1):538. doi:10.1186/s12879-016-1876-527716164
   PubMed Web of Science ®Google Scholar
• Clancy CJ, Chen L, Shields RK, et al. Epidemiology and molecular characterization of bacteremia due to carbapenem-resistant Klebsiella pneumoniae in transplant recipients. Am J Transplant. 2013;13(10):2619–2633. doi:10.1111/ajt.1242424011185
   PubMed Web of Science ®Google Scholar
• Villegas MV, Pallares CJ, Escandón-Vargas K. Characterization and clinical impact of bloodstream infection caused by carbapenemase-producing Enterobacteriaceae in seven Latin American Countries. PLoS One. 2016;11(4):e0154092. doi:10.1371/journal.pone.015409227104910
   PubMed Web of Science ®Google Scholar
• Kohler PP, Volling C, Green K, Uleryk EM, Shah PS, McGeer A. Carbapenem resistance, initial antibiotic therapy, and mortality in Klebsiella pneumoniae bacteremia: a systematic review and meta-analysis. Infect Control Hosp Epidemiol. 2017;38(11):1319–1328. doi:10.1017/ice.2017.19728950924
   PubMed Web of Science ®Google Scholar
• Falagas ME, Tansarli GS, Karageorgopoulos DE, Vardakas KZ. Deaths attributable to carbapenem-resistant Enterobacteriaceae infections. Emerg Infect Dis. 2014;20(7):1170–1175. doi:10.3201/eid2007.12100424959688
   PubMed Web of Science ®Google Scholar
• Benattar YD, Omar M, Zusman O, et al. The effectiveness and safety of high-dose colistin: prospective cohort study. Clin Infect Dis. 2016;63(12):1605–1612. doi:10.1093/cid/ciw68427794023
   PubMed Web of Science ®Google Scholar
• Liu YY, Wang Y, Walsh TR, et al. Emergence of plasmid-mediated colistin resistance mechanism MCR-1 in animals and human beings in China: a microbiological and molecular biological study. Lancet Infect Dis. 2016;16(2):161–168. doi:10.1016/S1473-3099(15)00424-726603172
   PubMed Web of Science ®Google Scholar
• Sheu CC, Chang YT, Lin SY, Chen YH, Hsueh PR. Infections caused by carbapenem-resistant Enterobacteriaceae: an update on therapeutic options. Front Microbiol. 2019;10:80. doi:10.3389/fmicb.2019.0008030761114
   PubMed Web of Science ®Google Scholar
• Zasowski EJ, Rybak JM, Rybak MJ. The β-lactams strike back: ceftazidime-avibactam. Pharmacotherapy. 2015;35(8):755–770. doi:10.1002/phar.162226289307
   PubMed Web of Science ®Google Scholar
• Shirley M. Ceftazidime-avibactam: a review in the treatment of serious gram-negative bacterial infections. Drugs. 2018;78(6):675–692. doi:10.1007/s40265-018-0902-x29671219
   PubMed Web of Science ®Google Scholar
• Krapp F, Grant JL, Sutton SH, Ozer EA, Barr VO. Treating complicated carbapenem-resistant Enterobacteriaceae infections with ceftazidime/avibactam: a retrospective study with molecular strain characterisation. Int J Antimicrob Agents. 2017;49(6):770–773. doi:10.1016/j.ijantimicag.2017.01.01828389354
   PubMed Web of Science ®Google Scholar
• Shields RK, Potoski BA, Haidar G, et al. Clinical outcomes, drug toxicity, and emergence of ceftazidime-avibactam resistance among patients treated for carbapenem-resistant Enterobacteriaceae infections. Clin Infect Dis. 2016;63(12):1615–1618. doi:10.1093/cid/ciw63627624958
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Trecarichi EM, Corona A, et al. Efficacy of ceftazidime-avibactam salvage therapy in patients with infections caused by Klebsiella pneumoniae carbapenemase-producing K. pneumoniae. Clin Infect Dis. 2019;68(3):355–364. doi:10.1093/cid/ciy49229893802
   PubMed Web of Science ®Google Scholar
• Castón JJ, Lacort-Peralta I, Martín-Dávila P, et al. Clinical efficacy of ceftazidime/avibactam versus other active agents for the treatment of bacteremia due to carbapenemase-producing Enterobacteriaceae in hematologic patients. Int J Infect Dis. 2017;59:118–123. doi:10.1016/j.ijid.2017.03.02128392315
   PubMed Web of Science ®Google Scholar
• De la Calle C, Rodríguez O, Morata L, et al. Clinical characteristics and prognosis of infections caused by OXA-48 carbapenemase-producing Enterobacteriaceae in patients treated with ceftazidime-avibactam. Int J Antimicrob Agents. 2019;53(4):520–524. doi:10.1016/j.ijantimicag.2018.11.01530471403
   PubMed Web of Science ®Google Scholar
• Sousa A, Pérez-Rodríguez MT, Soto A, et al. Effectiveness of ceftazidime/avibactam as salvage therapy for treatment of infections due to OXA-48 carbapenemase-producing Enterobacteriaceae. J Antimicrob Chemother. 2018;73(11):3170–3175. doi:10.1093/jac/dky29530099490
   PubMed Web of Science ®Google Scholar
• Shields RK, Nguyen MH, Chen L, Press EG, Kreiswirth BN, Clancy CJ. Pneumonia and renal replacement therapy are risk factors for ceftazidime-avibactam treatment failures and resistance among patients with carbapenem-resistant Enterobacteriaceae infections. Antimicrob Agents Chemother. 2018;62(5). doi:10.1128/AAC.02497-17
   Web of Science ®Google Scholar
• Horan TC, Andrus M, Dudeck MA. CDC/NHSN surveillance definition of health care-associated infection and criteria for specific types of infections in the acute care setting. Am J Infect Control. 2008;36(5):309–332. doi:10.1016/j.ajic.2008.03.00218538699
   PubMed Web of Science ®Google Scholar
• Castón JJ, Gallo M, García M, et al. Ceftazidime-avibactam in the treatment of infections caused by KPC-producing Klebsiella pneumoniae: factors associated with clinical efficacy in a single-center cohort. Int J Antimicrob Agents. 2020;56(3):106075. doi:10.1016/j.ijantimicag.2020.10607532629116
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Raffaelli F, Giannella M, et al. Ceftazidime-avibactam use for Klebsiella pneumoniae carbapenemase-producing K. pneumoniae infections: a retrospective observational multicenter study. Clin Infect Dis. 2021;73(9):1664–1676. doi:10.1093/cid/ciab17633618353
   PubMed Web of Science ®Google Scholar
• Gutiérrez-Gutiérrez B, Salamanca E, de Cueto M, et al. Effect of appropriate combination therapy on mortality of patients with bloodstream infections due to carbapenemase-producing Enterobacteriaceae (INCREMENT): a retrospective cohort study. Lancet Infect Dis. 2017;17(7):726–734. doi:10.1016/S1473-3099(17)30228-128442293
   PubMed Web of Science ®Google Scholar
• Temkin E, Torre-Cisneros J, Beovic B, et al. Ceftazidime-avibactam as salvage therapy for infections caused by carbapenem-resistant organisms. Antimicrob Agents Chemother. 2017;61(2). doi:10.1128/AAC.01964-16
   PubMed Web of Science ®Google Scholar
• Tumbarello M, Trecarichi EM, De Rosa FG, et al. Infections caused by KPC-producing Klebsiella pneumoniae: differences in therapy and mortality in a multicentre study. J Antimicrob Chemother. 2015;70(7):2133–2143. doi:10.1093/jac/dkv08625900159
   PubMed Web of Science ®Google Scholar
• King M, Heil E, Kuriakose S, et al. Multicenter study of outcomes with ceftazidime-avibactam in patients with carbapenem-resistant Enterobacteriaceae infections. Antimicrob Agents Chemother. 2017;61(7). doi:10.1128/AAC.00449-17
   Web of Science ®Google Scholar
• Sader HS, Huband MD, Duncan LR, Flamm RK. Ceftazidime-avibactam antimicrobial activity and spectrum when tested against gram-negative organisms from pediatric patients: results from the INFORM surveillance program (United States, 2011–2015). Pediatr Infect Dis J. 2018;37(6):549–554. doi:10.1097/INF.000000000000185929206750
   PubMed Web of Science ®Google Scholar
• Bradley JS, Roilides E, Broadhurst H, et al. Safety and efficacy of ceftazidime-avibactam in the treatment of children ≥3 months to <18 years with complicated urinary tract infection: results from a phase 2 randomized, controlled trial. Pediatr Infect Dis J. 2019;38(9):920–928. doi:10.1097/INF.000000000000239531335570
   PubMed Web of Science ®Google Scholar